Clinical Trial Update: Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome [Phase 2, Phase 3]

View source ↗

Summary

Phase 2 and Phase 3 clinical trials are evaluating antiangiogenic therapy with bevacizumab for retinopathy of prematurity. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Asociación para Evitar la Ceguera en México | Conditions: Retinopathy of Prematurity | Phase 2, Phase 3 | Status: RECRUITING